Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IOmet Pharma Ltd.

Division of Merck & Co. Inc.
iometpharma.com

Latest From IOmet Pharma Ltd.

BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight

Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.

ImmunoOncology Business Strategies

Scrip's Rough Guide To IDO

IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.

ImmunoOncology Research & Development

Biopharma Quarterly Dealmaking Statistics, Q1 2016

Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Alan Wise, PhD, CEO
    Peter Trill, CFO
  • Contact Info
  • IOmet Pharma Ltd.
    Nine Edinburgh BioQuarter
    Little France
    Edinburgh, EH16 4UX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register